The most widely used TKIs in the clinic to treat GBM are gefitinib and erlotinib (inhibit EGFR), imatinib mesylate (inhibits PDGFR), and sunitinib, vandetanib, and vatalanib (inhibit VEGF). This evidence concerns the gene EGFR and glioblastoma.